Scienture Holdings, Inc. 8K

Scienture Holdings, Inc. announced strong Q2 2026 revenue growth and margin improvement, supported by the commercial launch and expanded patent and payer coverage for its products Arbli and REZENOPY.

Scienture Holdings, Inc. (NASDAQ: SCNX) reported its financial and operational results for the quarter and six months ended June 30, 2026, highlighting approximately 510% sequential revenue growth to $343,639 versus Q1 2026, gross margin of about 97.7%, a 48% year-over-year improvement in operating loss to approximately $2.7 million, and a 58% narrowing of net loss to approximately $2.8 million, while ending the quarter with roughly $11.2 million in cash, cash equivalents and restricted cash; operationally, the company commenced the commercial launch of its second product REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg, secured a second patent for REZENOPY and a third patent for Arbli (losartan potassium) oral suspension extending IP protection to 2041, and expanded payer coverage and commercial access for both products.

Filing Facts

CIK

1382574

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-039474

Alert Tier

7